W. Macaron

发表

Hyperleukocytosis and leukostasis in acute and chronic leukemias

N. Short, Zaven Sargsyan, W. Macaron, 2022, Leukemia & lymphoma.

A multi-arm phase Ib/II study designed for rapid, parallel evaluation of novel immunotherapy combinations in relapsed/refractory acute myeloid leukemia

M. Konopleva, Z. Estrov, M. Andreeff, 2022, Leukemia & lymphoma.

A Phase II Study of Azacitidine, Venetoclax, and Trametinib in Relapsed or Refractory Acute Myeloid Leukemia Harboring RAS Pathway-Activating Mutations

M. Konopleva, T. Kadia, F. Ravandi, 2022, Acta Haematologica.

Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial.

G. Garcia-Manero, Xuelin Huang, K. Patel, 2022, The Lancet. Haematology.

Differential prognostic impact of RUNX1 mutations according to frontline therapy in patients with acute myeloid leukemia

K. Bhalla, K. Patel, T. Kadia, 2022, American journal of hematology/oncology.

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.

K. Rezvani, G. Garcia-Manero, Xuelin Huang, 2022, The Lancet. Haematology.

Clinical outcomes and impact of therapeutic intervention in patients with acute myeloid leukemia who experience measurable residual disease (MRD) recurrence following MRD‐negative remission

H. Kantarjian, E. Shpall, K. Patel, 2022, American journal of hematology.

High-sensitivity next-generation sequencing MRD assessment in ALL identifies patients at very low risk of relapse

M. Konopleva, H. Kantarjian, G. Garcia-Manero, 2022, Blood advances.

P371: HYPER-CVAD WITH SEQUENTIAL BLINATUMOMAB, WITH OR WITHOUT INOTUZUMAB OZOGAMICIN, IN ADULTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA

T. Kadia, F. Ravandi, E. Jabbour, 2022, HemaSphere.

A phase II study of hyper-CVAD with sequential blinatumomab (Blina), with or without inotuzumab ozogamicin (INO), in adults with newly diagnosed B-cell acute lymphoblastic leukemia (ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2022, Journal of Clinical Oncology.

Updated results from a phase II study of mini-hyper-CVD (mini-HCVD) plus inotuzumab ozogamicin (INO), with or without blinatumomab (Blina), in older adults with newly diagnosed Philadelphia chromosome (Ph)-negative B-cell acute lymphoblastic leukemia (ALL).

M. Konopleva, H. Kantarjian, T. Kadia, 2022, Journal of Clinical Oncology.

Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome‐negative B‐cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab

M. Konopleva, H. Kantarjian, T. Kadia, 2022, American journal of hematology.

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

M. Konopleva, G. Garcia-Manero, E. Shpall, 2022, Journal of Hematology & Oncology.

Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study

G. Garcia-Manero, Xuelin Huang, T. Kadia, 2022, Blood.

Liquid biopsies and minimal residual disease in lymphoid malignancies

C. Chaulagain, Sabine Allam, Morgan Bou Zerdan, 2023, Frontiers in Oncology.

Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1

K. Patel, F. Ravandi, E. Jabbour, 2023, American journal of hematology.

Updated Results from a Phase I/II Study of the Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia

G. Garcia-Manero, T. Kadia, F. Ravandi, 2022, Blood.

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

M. Andreeff, G. Garcia-Manero, J. Cortes, 2023, Journal of Hematology & Oncology.

Palbociclib and letrozole in hormone-receptor positive advanced breast cancer: Predictive response and prognostic factors.

J. Kattan, F. Farhat, Marianne Smith, 2022, Current Problems in Cancer.

A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2023, Journal of Clinical Oncology.

S118: A CHEMOTHERAPY-FREE COMBINATION OF PONATINIB AND BLINATUMOMAB FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA: SUBGROUP ANALYSIS FROM A PHASE II STUDY

M. Konopleva, Xuelin Huang, T. Kadia, 2023, HemaSphere.

A phase II trial of ponatinib and blinatumomab in adults with newly diagnosed Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).

H. Kantarjian, Xuelin Huang, T. Kadia, 2023, Journal of Clinical Oncology.

S119: COMBINATION OF MINI-HYPER-CVD AND INOTUZUMAB (INO) FOLLOWED BY BLINATUMOMAB (BLINA) CONSOLIDATION IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL): A PHASE II TRIAL

G. Garcia-Manero, Xuelin Huang, T. Kadia, 2023, HemaSphere.

P358: HYPER-CVAD WITH BLINATUMOMAB AND INOTUZUMAB OZOGAMICIN FOR PATIENTS WITH NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-NEGATIVE B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA: A PHASE II STUDY

T. Kadia, F. Ravandi, E. Jabbour, 2023, HemaSphere.

A phase II trial of a chemotherapy-free combination of ponatinib and blinatumomab in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).

H. Kantarjian, T. Kadia, F. Ravandi, 2022, Journal of Clinical Oncology.

Genomic determinants of response and resistance to inotuzumab ozogamicin in B-cell ALL

H. Kantarjian, N. Short, K. Roberts, 2023, medRxiv.